Printer Friendly
The Free Library
19,111,409 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cordis Cardiology Introduces the MINI Crown Stent.


MIAMI--(BUSINESS WIRE)--April 19, 1999--

FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 Clears Coronary Artery coronary artery
n.
1. An artery with origin in the right aortic sinus; with distribution to the right side of the heart in the coronary sulcus, and with branches to the right atrium and ventricle, including the atrioventricular branches and
 Stent Specifically

Engineered for Smaller Vessels

Cordis Cardiology today announced U.S. Food and Drug Administration approval to market its new MINI Crown stent (the MINI) specifically engineered for smaller coronary vessels (lumen diameters from 3.25 mm to as small as 2.25 mm). Cordis Cardiology is a unit of Cordis Corporation, a Johnson & Johnson company.

According to according to
prep.
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

3.
 David O. Williams, M.D., Division of Cardiology, Rhode Island Hospital Rhode Island Hospital is a private, not-for-profit hospital located in Providence, Rhode Island. The hospital has 719 beds, and an acute care hospital and an academic medical center. Rhode Island Hospital was founded during the American Civil War in 1863. , Providence, RI, who served as principal investigator Noun 1. principal investigator - the scientist in charge of an experiment or research project
PI

scientist - a person with advanced knowledge of one or more sciences
 in the clinical trial of the MINI, many physicians view smaller vessel stenting as the next frontier in interventional cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based .

"There's no question that there is high physician demand for a quality smaller vessel stent," said Dr. Williams. "I find the MINI to be the best choice for stenting smaller vessels. It offers many unique advantages, such as one-step deployment, a low-profile delivery system, minimal balloon overhang Overhang

Calculated as stock options granted, plus the remaining options to still be granted, and then divided by the total shares outstanding.

Notes:
A high percentage for the overhang is usually a bad thing.
, and precise balloon sizing at higher pressures--all of which, in my opinion, make the procedure safe."

Jesse Penn, president, Cordis Cardiology, said the company initially will offer the MINI in 11 mm and 15 mm lengths and diameters ranging from 3.25 mm to 2.25 mm in quarter sizes. Penn described the MINI as the stent that enables physicians to `go smaller safely,' predicting that it will soon become the `gold standard' for smaller vessel stenting.

Penn also explained that the MINI and the Dynasty(TM) delivery system have been carefully designed to respond to the need for a stenting system that offers easy deliverability in patients with small, tight lesions while minimizing the risks of edge dissection and stent embolization embolization /em·bo·li·za·tion/ (em?bo-li-za´shun)
1. the process or condition of becoming an embolus.

2. therapeutic introduction of a substance into a vessel in order to occlude it.
.

"We're addressing the issue of edge dissection by 1) using the new non-compliant(a) DURAMAX(TM) balloon material to control expansion and 2) closely matching balloon and stent lengths to limit balloon overhang to 1 mm, thus greatly reducing the potential for what cardiologists describe as dog boning dog boning Interventional cardiology A complication caused when an angioplasty balloon becomes excessively expanded at either end of a stent–likened to a dog bone. See Stent. ,"(b) said Penn. "To minimize the risk of stent embolization, Cordis' proprietary Nesting(TM) technology secures the MINI to the delivery balloon until it is deployed."

"Clinical trial results show the MINI to be associated with a high rate of successful deployment, outstanding angiographic outcomes, and a very low rate of post-stenting major adverse cardiac events," said Dr. Williams. "While the MINI is an excellent stent for treating smaller vessels, I was also extremely impressed with its performance in vessels with lumen diameters of 3.0 mm to 3.25 mm."

Historically, most smaller vessel lesions have been treated with balloon angioplasty balloon angioplasty: see under angioplasty.  alone due to the small lumen size of these vessels and the increased risk of dissection. Dr. Williams noted that the use of large-vessel stent systems in small-diameter vessels generally doesn't allow for a proper stent-to-artery ratio when deployed.

The MINI is indicated for treatment of abrupt or threatened closure in patients with failed interventional therapy in native coronary lesions (less than or equal to 25 mm) with reference diameters in the range of 3.25 mm to 2.25 mm.

(a) Non-compliant: Term used to describe balloon material that

provides predictable and controllable expansion to minimize the

risk of edge dissection.

(b) Dog boning: Term used to describe the appearance of excessive

expansion of the balloon on either end of the stent.

Cordis Cardiology is a subsidiary of Cordis Corporation, a broad-based supplier of products for circulatory disease management. Established in 1959, Cordis Corporation is the world's largest, most comprehensive developer and manufacturer of innovative products for interventional medicine, minimally invasive computer-based imaging, and electrophysiology. In 1996, Cordis Corporation merged with Johnson & Johnson to form Cordis, a Johnson & Johnson company, with approximately 3,500 employees worldwide.

To participate in an audioconference on Wednesday, April 21, from 10:00 to 11:00 AM (EST EST electroshock therapy.

EST
abbr.
electroshock therapy
) with Dr. David Williams David Williams is the name of: Musicians
  • David Williams (didgeridoo), (born 1983) Aboriginal musician and artist
  • David Williams (Son of Dork), a guitarist in the British band Son of Dork
 and Cordis Cardiology executives, please call 800-670-3547 (at 10:00 AM EST, April 21). Should you encounter any problems getting a connection, please call D.J. Storch & Associates at 908-273-1400.

-- Complete taped audioconference can be heard April 21, between

12:00 and 8:00 PM (EST), by calling 800-633-8284. Callers will be

prompted to enter the following access code number: 12198935.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 19, 1999
Words:695
Previous Article:Princeton Softech's SyncPoint Transforms Enterprise Data to eData.
Next Article:SynaPix Launches Product Line at NAB'99; SynaFlex and MatchMaker Pioneer Next Wave in Visual Effects Creation.
Topics:



Related Articles
Cardio Technologies, Inc. Announces Key Additions to Management Team in Finance, Marketing, Engineering.
FDA Approves CrossFlex LC - New "Workhorse" Coronary Artery Stent from Cordis Cardiology.
Guidant and Johnson & Johnson Announce Comprehensive Technology Agreement; Guidant Acquires Exclusive Option to Impulse Dynamics Heart Failure...
BMC Industries Announces Development and Supply Agreement With Cordis Corporation.
Things just mesh: making stents even better at keeping arteries open.
Cook Incorporated Settles Stent Patent Litigation Filed Against Cordis, SooHo-Life Partners.
PEMSTAR to Provide Equipment and Manufacturing Services for Cordis Corporation's CYPHER Sirolimus-eluting Stent.
TAKING AIM AT CLOGGED ARTERIES AV HOSPITAL OFFERING NEW BREAKTHROUGH.
The three R's: radiation for restenotic renals?
AVI BioPharma Provides Cardiovascular Program Update; Notice of Allowance of Two Patents Strengthens Cardiovascular Restenosis Program.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles